Background: Increasingly, patients with thyroid nodule cytology labeled AUS/FLUS, or FN undergo diagnostic analysis with the Afirma gene expression classifier (GEC). No long-term, multi-site analysis of Afirma GEC performance has yet been performed.
T
he diagnostic strategy for evaluating thyroid nodules has rapidly evolved. Addressing inherent limitations to fine needle aspiration (FNA) cytology, molecular analysis of aspirated tissue has emerged as an important tool for assessing cytologically indeterminate nodules (1) . While many molecular markers have been proposed, only a small minority have proven robust enough to modify clinical decision making, and thus impact care. This is especially true with regards to diagnostic markers designed to confidently predict a benign diagnosis despite abnormal cytology (2, 3, 4) . Traditionally, indeterminate FNA cytology raises concern for thyroid cancer and be-cause of this, patients are often referred for diagnostic surgery. However, over half of such patients prove to have benign disease following histopathologic interpretation (5) . For these patients, surgery was unnecessary, yet subjected them to morbidity, operative risk, and excess cost.
The Afirma diagnostic test is a gene expression classifier (GEC) measuring the expression of 167 gene transcripts, and recommended for use in cytologically indeterminate thyroid nodules. It classifies aspirated material from thyroid nodules as either benign or suspicious, and was designed a priori to maximize test sensitivity and negative predictive value (NPV). Results of a prospective, multicenter, blinded validation demonstrated the test's ability to accurately identify many benign thyroid nodules even when cytologically indeterminate (6) . A benign Afirma GEC result, when applied to nodules with FNA cytology labeled atypical (or follicular lesion) of undetermined significance (AUS/FLUS) or follicular neoplasm (FN), proved benign in 95% and 94% cases, respectively. Such accuracy approaches that of a benign cytologic result (7) and allows consideration of nonsurgical management.
A follow-up study demonstrated that nonsurgical management is preferred in the vast majority of cytologically indeterminate -Afirma GEC benign cases (8) However, the above findings were obtained as parts of a blinded validation trial, where protocol and enrollment are tightly managed. Understanding how the Afirma GEC performs in a clinical setting remains unclear. For this reason, continued clinical surveillance is paramount. Following completion of the initial validation trial, five academic centers tracked their experience with the Afirma GEC among its intended use population. To date, 346 consecutive samples have been collected and represent the focus of this analysis. We sought to analyze the diagnostic performance and utility of the Afirma GEC in the clinical setting, and its impact upon clinical decision making.
Materials and Methods
We retrospectively collected data from all patients with cytologically indeterminate thyroid nodules who underwent testing with the Afirma GEC between September 1, 2010 and January 10, 2013 at one of five U.S. medical centers, each with expertise in thyroid nodule evaluation. These medical centers included the Brigham & Women's Hospital, the University of Colorado Hospital, the University of Pennsylvania Hospital, the Ohio State Medical Center, and the University of Cincinnati Medical Center. Patients were referred for the evaluation of thyroid nodules Ն 1cm in maximal diameter. All underwent clinical and sonographic evaluation. Ultrasound was first performed and confirmed the presence of a clinically relevant thyroid nodule. Fine needle aspiration was performed with ultrasound-guidance, most often using a 25-gauge needle and involving 2-4 needle passes. FNA cytology was prepared by smear-or liquid-based processes, and read internally by experienced cytopathologists at each separate institution. In some but not all instances, smearbased cytology preparation allowed for rapid on-site assessment (ROSE) to determine the need for Afirma testing during the same visit. Cytology results were classified according to the Bethesda System for Reporting Thyroid Cytopathology (9) . When classified as AUS/FLUS, FN, or (rarely) Suspicious for malignancy (SUSP), separate secondary aspirations were processed for Afirma GEC analysis at the discretion of the treating physician [Currently, Veracyte, Inc. recommends the Afirma GEC be performed only on nodules with cytology classified as AUS/FLUS or FN]. Clinical decisions, including recommendations for surgical resection, were made thereafter by the treating physician based upon all available data.
For each subject, we collected demographic, sonographic, cytologic, histopathologic, and Afirma GEC data. Nodule size and cystic content were assessed sonographically. We documented if thyroid surgery was recommended by the treating physician, and if surgery was performed by the time of the analysis. If surgery was performed, final histopathology interpretation was obtained and the date and extent of surgery were documented. Specifically, we queried if patients underwent hemi-thyroidectomy vs near-total thyroidectomy. If surgery was not performed we queried all subsequent clinical and followup data in attempt to determine the status of each individual and thyroid nodule.
For this investigation, our prespecified endpoints were to first independently validate the proportion of benign vs suspicious Afirma results obtained from cytologically indeterminate nodules, and. investigate how these results modified clinical care recommendations and resource utilization. If surgery was performed, we sought to determine the proportion of "cytologically indeterminate /Afirma suspicious" nodules that proved malignant upon postsurgical histopathologic assessment. Finally, we investigated the clinical utility of the Afirma GEC by assessing follow-up status of patients with indeterminate cytology but a benign Afirma GEC result.
IRB approval was obtained for this investigation. Statistical analysis was performed using the 2 or student's t test, as applicable. P-values Ͻ 0.05 were considered significant. This study did not receive any financial support, approbation or review by Veracyte, Inc., or any other commercial entity. Dr. Alexander has served or currently serves as a consultant for Asuragen, Inc., Veracyte, Inc., and Genzyme, Inc. (past), with Veracyte stock options.
Results
346 Afirma GEC analyses were performed between March 1, 2010 and January 10, 2013. Upon review, 7 cases (2%) did not meet our entry criteria, and were excluded prior to knowledge of their Afirma GEC result. Specifically, 4 nodules were first considered AUS upon rapid on-site evaluation though final cytopathology was interpreted as 'benign'; and, 3 nodules had nondiagnostic FNA cytology. The remaining 339 cases define our study cohort. The enrollment from each institution, as well as patient and nodule characteristics, are shown in Table 1 .
165 of 339 (49%) nodules were cytologically atypical (or follicular lesion) of undetermined significance (AUS/ FLUS). Afirma GEC analyses of these nodules were "benign" in 91 of 165 (55%) cases, "suspicious" in 66 of 165 (40%), and "nondiagnostic" in 8 of 167 (5%) cases. Separately, 161 of 339 (47%) nodules were cytologically classified as follicular neoplasm (FN). Afirma GEC analyses of these nodules were "benign" in 79 of 161 (49%) cases, "suspicious" in 73 of 161 (45%), and "nondiagnostic" in 9 of 161 (6%) cases. A "nondiagnostic" GEC result is generally due to insufficient or poor quality RNA. Finally, 13 of 339 nodules were cytologically suspicious for malignancy (SUSP). Afirma GEC analyses of these nodules were "benign" in 4 of 13 (31%) cases, and "suspicious" in 9 of 13 (69%) cases. In total, 174 of 339 (51%) cytologically indeterminate nodules were Afirma "benign", while 148 (44%) of the cytologically indeterminate nodules
were Afirma "suspicious". Seventeen of 341 (5%) were Afirma "nondiagnostic". These data are shown in Table 2 . Among patients with cytologically indeterminate nodules, the Afirma GEC result substantially impacted clinical care recommendations. Patients with indeterminate cytology and "suspicious" Afirma GEC results were recommended for surgery in 141 of 148 (95%) cases. In contrast, patients with indeterminate cytology but a "benign" Afirma GEC result were recommended for surgery in only 4 of 174 (2%) cases (P Ͻ .01) supporting previous findings regarding the clinical impact of this test upon care recommendations (8) . Patients with indeterminate cytology and "nondiagnostic" Afirma GEC results were recommended for surgery in 4 of 17 (34%) cases. Following an intentionto-treat assumption in which thyroid surgery is typically recommended for patients with cytologically indetermi- Figure 1) . Of the 141 patients with indeterminate cytology and "suspicious" Afirma GEC results who were recommended for thyroid surgery, 121 (86%) completed surgery. Specifics of the 20 patients who did not complete surgery are as follows: 7 patients declined the recommendation, 5 separate patients were lost to follow-up, and 7 have committed to future surgery which has not yet been performed; 1 additional patient died of a separate cause. We next sought to validate the malignancy rate among patients with cytologically indeterminate and "suspicious" Afirma GEC nodules. These data are shown in Table 3 . Together, 53 of121 (44%) cytologically indeterminate/"suspicious" Afirma GEC nodules proved malignant following histopathologic assessment. As expected, most the malignant lesions were papillary thyroid carcinoma (87%).
Of the 174 patients with indeterminate cytology and "benign" Afirma GEC results, only four patients were immediately recommended for surgery (2%). Corresponding FNA cytology was AUS/FLUS in three nodules, and SUSP in one nodule. Of the remainder, 71 (41%) had documented followup at a mean of 8.5 months (median 8 months; range 1-24 months) following GEC testing. In ten of these 71 patients, a followup clinical examination was performed, while the remaining 61 underwent repeat sonographic assessment. Ultimately, 11 of these patients (inclusive of the 4 immediately recommended for surgery above) underwent thyroid surgery, most because of personal preference or compressive symptoms in the neck. 10 of these 11 cases proved benign histologically, while 1 was confirmed malignant (1.0cm sonographic nodules which proved a 0.6cm papillary carcinoma histologically). Uniquely, a separate patient's nodule histology revealed a micropapillary carcinoma (0.8cm) confirmed within a 3.2cm nodule, though most nodular tissue was assessed as benign. Importantly, 17 patients with indeterminate FNA cytology, but benign Afirma GEC results had clinical followup of 12 months or more (range 12-24months). 3 of these 17 patients ultimately underwent surgical removal of the nodule due to compressive symptoms (n ϭ 2) or nodule growth (n ϭ 1). All 3 nodules were benign histologically. The remaining 14 patients were assessed with ultrasound, and no nodule change or evidence of malignancy was detected over this 12-24 months time period.
Finally, we investigated the performance of the Afirma GEC by individual site, to better understand practice variation. These data are shown in Table 4 , and also depict the site-specific estimates of malignancy prevalence for each cytologic category. The proportion of nodules cytologically AUS/FLUS but subsequently found to be Afirma GEC benign ranged from 42%-71%, while those nodules cytologically FN but subsequently found to be Afirma GEC benign ranged from 38%-67%. The proportion of cytologically indeterminate/Afirma GEC suspicious nodules that proved cancerous following histopathologic assessment ranged from 33%-55% between sites. These differences were not statistically significant.
Discussion
Molecular diagnostic tests are increasingly recommended for the evaluation of cytologically indeterminate thyroid nodules. While analytic (laboratory) validity has been established for most such markers, clinical validity and clinical utilization is lacking for all but a few. This point is worthy of emphasis, as blinded, multicenter clinical validation, as well as postmarketing surveillance, are necessary for full understanding of a test's clinical impact within a diverse and heterogeneous population. Presently, few data exist which describe Afirma GEC performance in the live clinical setting. We investigated 346 consecutive patients with indeterminate thyroid nodule cytology who underwent Afirma analysis in one of five expert centers. Overall, 51% of cytologically indeterminate nodules were "benign" by Afirma GEC testing. As might be expected, the proportion of "suspicious" Afirma results increased when applied to cytologically AUS/FLUS (40%), FN/SFN (45%), and SUSP nodules (69%), respectively. In total, "cytologically indeterminate / Afirma GEC suspicious" nodules proved cancerous in 44% of patients following surgical removal. Most notably, a benign Afirma GEC result dramatically altered clinical care recommendations, as 95% of Afirma GEC "suspicious" nodules were referred for thyroid surgery in comparison to only 2% of Afirma GEC "benign" nodules. Follow-up clinical assessment confirms a low rate of false negativity among Afirma benign nodules. Together, these independent data externally validate many of the findings from the initial blinded investigation, while demonstrating the power of thyroid nodule molecular analysis to modify clinical practice. Our findings support continued recommendations for a conservative approach toward most patients with cytologically indeterminate nodules when Afirma GEC testing returns benign. This recommendation holds true across a wide range of geographic regions and patient demographics.
In the initial multicenter validation (6), 100 of 265 (38%) cytologically indeterminate nodules were benign on Afirma analysis. While our study documented 174 of 339 (51%) such nodules as benign on Afirma analysis, it is worth noting important study differences. The original validation sought to enroll patients inclusive of all cytologically indeterminate subtypes, and demonstrated the expected distribution of AUS/FLUS, FN, and SUSP findings. However, it is notable that Afirma GEC testing was thereafter only recommended for use in nodules with AUS/ FLUS and/or FN cytology. Our study demonstrates adherence to this recommendation within clinical practice, while also explaining an increased proportion of benign Afirma results. 326 of 339 (96%) cytologically indeterminate samples were labeled AUS/FLUS and/or FN. As these are indeterminate categories that imply a lower malignant risk in comparison to SUSP cytology, it is logical to anticipate a higher proportion of Afirma GEC benign results in these populations.
Our investigation demonstrates variability in cytology distribution as well as Afirma GEC performance across the five different participating study sites. This finding is worthy of discussion. While caution should be taken in direct site-to-site comparison when enrollment is variable across locations, our data nonetheless demonstrate that the proportion of samples which prove to be Afirma 'benign' may vary up to 25%. Nationally, we also note that many thyroid nodule FNA samples are cytologically evaluated at a central cytology practice in Austin, Texas (and not internal to each medical center) prior to Afirma GEC analysis. Performance at such a practice may be similar or vary in comparison to our data. Unfortunately, there exist no published results to allow such analysis. Most importantly, these data clarify that site-to-site variation regarding the implied meaning of each cytology diagnoses may occur. We note that many prior publications have also demonstrated poor inter-rater (and intra-rater) cytology concordance even among experts (10, 11) . Thus, it is increasingly believed that such modest variation appears unavoidable (12) , and supports the need for synergistic cytologic and molecular analysis of thyroid nodules within this population. These data also support a recommendation that pretest probability of malignancy be individually assessed at each practice locale, and to the best extent possible, prior to Afirma GEC interpretation.
Our data demonstrate a substantial change in practice patterns following the availability of the Afirma GEC (13). Among five major medical centers, clinical recommendations for surgery dropped 93% among patients with cytologically indeterminate thyroid nodules. We note some patients (n ϭ 11) nonetheless pursued surgery even if Afirma GEC was benign, while others (n ϭ 20) did not comply with surgical recommendations. Nonetheless, in an academic clinical setting, a 76% reduction in surgery was observed when the Afirma GEC was applied to patients in whom surgery would otherwise have been typically performed. Follow up assessment of those with Afirma GEC benign results confirms a very low rate of false negative results, and provides support for the clinical utility of this test. We acknowledge, however, that cytologic nor Afirma GEC results alone should mandate an exact clinical recommendation for all patients. Individualized clinical risk assessment and personalized care recommendations should always be pursued (14) , as clinical symptoms, nodule size, and/or sonographic findings can at times be enough to warrant intervention regardless of molecular analysis. We acknowledge limitations to our study. Our data are retrospective in nature, allowing for associated referral and sample bias. However, this study was purposefully designed with such intent, to best analyze Afirma GEC performance in a clinical environment. We also acknowledge these data do not capture all outcome measures. Only 41% of patients with Afirma GEC benign results have documented assessment of their subsequent clinical status. It is notable, however, that such variability is inevitable as there exist no data confirming a specific strategy of recommended repeat assessment. At present, expert opinion of this matter remains highly variable, leading to diverse practice patterns (13, 15, 16) . Nonetheless, only 1 of 71 patients with an Afirma GEC benign result demonstrated subsequent malignancy. We also note that many thyroid nodule FNA samples are cytologically evaluated at a central cytology practice in Austin, Texas (and not internal to each medical center) prior to Afirma GEC analysis. Performance at such a practice may be similar or vary in comparison to our data.
In summary, these data provide the first extensive analysis of the Afirma GEC diagnostic test applied to a live, clinical environment. Analysis confirms test performance similar to that of the initial blinded validation, and engenders confidence that such data can be effectively translated into the everyday care of patients with cytologically 
